MetaVia obesity and diabetes drug data accepted for ADA 2026 conference presentations

Filed May 18, 2026 · Period ending May 18, 2026 · ~1 min read

Key Changes

• medium

  Three late-breaking abstracts on MetaVia's cardiometabolic drug candidates accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions in June, suggesting novel or significant clinical data.

  Item 8.01 view on EDGAR →
• medium

  DA-1726, a dual-receptor obesity treatment targeting both GLP-1 and glucagon receptors, will be featured in conference presentations alongside vanoglipel (DA-1241), a GPR119 agonist for diabetes.

  Press Release verify on EDGAR →